Silexion Therapeutics
SLXN
4 hedge funds and large institutions have $17.3K invested in Silexion Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 5 closing their positions.
3.5% less ownership
Funds ownership: 3.66% → 0.16% (-3.5%)
43% less funds holding
Funds holding: 7 → 4 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
87% less capital inflows, than outflows
Capital inflows: $27.9K | Capital outflows: $212K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Montag & Associates
Atlanta,
Georgia
|
+$25.9K |
| 2 |
PK
Pflug Koory
Omaha,
Nebraska
|
+$1.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wildcat Capital Management
New York
|
-$91.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$53.8K |
| 3 |
Meyer Handelman Company
Rye Brook,
New York
|
-$26.7K |
| 4 |
Moloney Securities Asset Management
Manchester,
Missouri
|
-$16.2K |
| 5 |
Virtu Financial
New York
|
-$12K |
SLXN Hedge Fund Activity: Q3 2025 in Review
4 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q3 2025, worth a combined $17.3K — down 93% from $258K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SLXN and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Montag & Associates, opening a new position worth an estimated $25.9K. The largest seller was Wildcat Capital Management, exiting entirely with an estimated $91.9K sold.
- 4 institutional investors held Silexion Therapeutics (SLXN) as of Q3 2025, down from 7 in Q2 2025.
- Funds reported $17.3K of Silexion Therapeutics stock for Q3 2025, down 93% quarter-over-quarter.
- 2 funds opened new Silexion Therapeutics positions in Q3 2025 and 5 closed out, a net change of -3 holders.
- The largest Silexion Therapeutics buyer in Q3 2025 was Montag & Associates, an estimated $25.9K added.
- The largest Silexion Therapeutics seller in Q3 2025 was Wildcat Capital Management, an estimated $91.9K sold.
Based on aggregated 13F filings for Q3 2025.